Full text
Earnings transcript
Read the complete earnings call transcript.
MRNA
Moderna, Inc.
$225
28
(14.21%)
| Exchange: | NASDAQ |
| Market Cap: | 89.277B |
| Shares Outstanding: | 376M |
Delayed data
About The Company
| Sector: | HealthcareView sector performance | |||||
| Industry: | BiotechnologyView industry performance | |||||
| CEO: | Stéphane Bancel | |||||
| Full Time Employees: | 4700 | |||||
| Address: |
| |||||
| Website: | https://www.modernatx.com |
Moderna, Inc., a biotechnology firm, is dedicated to the discovery, development, and commercialization of messenger RNA (mRNA) based therapies and preventive medicines. Its extensive research and development efforts target a broad spectrum of medical needs, including infectious diseases, cancer immunology, rare conditions, cardiovascular ailments, and autoimmune disorders, with operations spanning the United States, Europe, and other global markets. The company’s diverse product pipeline encompasses various vaccine candidates: those for respiratory illnesses like COVID-19, influenza, and respiratory syncytial virus (RSV); latent viral infections such as cytomegalovirus (CMV), Epstein-Barr virus (EBV), human immunodeficiency virus (HIV), herpes simplex virus (HSV), and varicella-zoster virus (VZV); and public health threats like Zika and Nipah. Additionally, Moderna is advancing systemic secreted and cell surface-targeted therapeutics, an array of cancer vaccines (including personalized, KRAS, and checkpoint varieties), intratumoral immuno-oncology products, localized regenerative treatments, systemic intracellular medicines, and inhaled pulmonary solutions. Moderna maintains strategic alliances with several prominent entities, including AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, Carisma Therapeutics, Inc., Metagenomi, Inc., the Defense Advanced Research Projects Agency (DARPA), the Biomedical Advanced Research and Development Authority (BARDA), the Institute for Life Changing Medicines, and The Bill & Melinda Gates Foundation. It also holds a collaboration and license agreement with Chiesi Farmaceutici S.P.A. Founded in 2010 as Moderna Therapeutics, Inc., the company officially became Moderna, Inc. in August 2018. Its corporate headquarters are located in Cambridge, Massachusetts.
Click to read more…
Revenue Segmentation
EPS
Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.
Earnings Call
AI summary
Key takeaways
Short, structured highlights from the call so you can focus on what matters.
Log in to continue
Log in to read the full transcript and AI-generated earnings summaries.
Login — it's freeIncome Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 6,848,000 | 3,199,000 | 1,944,000 |
| Gross Profit | 2,155,000 | 1,735,000 | 1,076,000 |
| EBITDA | -3,283,000 | -3,394,000 | -2,553,000 |
| Operating Income | -4,239,000 | -3,945,000 | -3,074,000 |
| Net Income | -4,714,000 | -3,561,000 | -2,822,000 |
(* All numbers are in thousands)
Balance Sheet
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total Assets | 18,426,000 | 14,142,000 | 12,338,000 |
| Total Liabilities | 4,572,000 | 3,241,000 | 3,688,000 |
| Total Stockholders Equity | 13,854,000 | 10,901,000 | 8,650,000 |
| Total Debt | 1,243,000 | 747,000 | 1,916,000 |
| Cash and Cash Equivalents | 2,907,000 | 1,927,000 | 2,595,000 |
(* All numbers are in thousands)
Cash Flow Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating Cash Flow | -3,118,000 | -3,004,000 | -1,873,000 |
| Capital Expenditure | -707,000 | -1,051,000 | -192,000 |
| Free Cash Flow | -3,825,000 | -4,055,000 | -2,065,000 |
| Net Income | -4,714,000 | -3,561,000 | -2,822,000 |
| Net Change in Cash | -289,000 | -999,000 | 668,000 |
(* All numbers are in thousands)
Analyst Estimates
| Fiscal Year | 2030 | Research Access | Research Access | Research Access | Research Access |
|---|---|---|---|---|---|
| Estimated Revenue (Low) | 6,172,739.701 | Research Access | Research Access | Research Access | Research Access |
| Estimated Revenue (High) | 10,394,993.268 | Research Access | Research Access | Research Access | Research Access |
| Estimated Revenue (Avg) | 7,559,387.500 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (Low) | 1,746,244.106 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (High) | 2,968,098.034 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (Avg) | 2,147,519.766 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (Low) | 1,012,360.832 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (High) | 1,977,625.435 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (Avg) | 1,329,368.603 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (Low) | 1,492,311.738 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (High) | 2,513,077.049 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (Avg) | 1,827,545.506 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (Avg) | 3.420 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (High) | 5.080 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (Low) | 2.600 | Research Access | Research Access | Research Access | Research Access |
| Number of Analysts (Estimated Revenue) | 14 | Research Access | Research Access | Research Access | Research Access |
| Number of Analysts (Estimated EPS) | 6 | Research Access | Research Access | Research Access | Research Access |
Log in to continue
Log in and subscribe to Full Access to see up to 5 years of analyst estimates.
Login — it's free(* All numbers are in thousands)
Current Key Metrics
Log in to continue
Log in to see all key valuation metrics and ratios for this symbol.
Login — it's freeForward P/E Ratios
Log in to continue
Log in with Full Access for forward P/E high/low estimates and the full multi-year table.
Login — it's freeSWOT Analysis
At what price to buy it? -
Intrinsic Value Calculator
Based on current fundamentals and analyst forecasts, MarketSnap estimates MRNA intrinsic value between $60.37 – $87.82 per share. This depends on revenue growth, margins, and discount rate.
This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.
[intrinsic_calculator]
Common questions about MRNA valuation
Is Moderna, Inc. (MRNA) overvalued or undervalued right now?
MarketSnap estimates intrinsic value for Moderna, Inc. (MRNA) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.
Is MRNA a buy, hold, or sell for long-term investors?
MarketSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether MRNA trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.
What is MRNA’s P/E ratio?
You can see MRNA’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.
How is intrinsic value calculated for MRNA?
MarketSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MarketSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.
Is MRNA a good long-term investment?
Whether MRNA fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MarketSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.
MRNA
1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.
Daily snapshot
14.21
Trading Metrics:
| Open: | 199.1 | Previous Close: | 197 | |
| Day Low: | 197.17 | Day High: | 225 | |
| Year Low: | 22.28 | Year High: | 225 | |
| Price Avg 50: | 134.92 | Price Avg 200: | 71.68 | |
| Volume: | 28.817M | Average Volume: | 15.371M |
Log in to continue
Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.
Login — it's free
